NR1H4 and metabolic dysfunction-associated steatotic liver disease: Nonetheless, CDCA has been confirmed as the main farnesoid X receptor (FXR) ligand, and FXR agonists are proposed treatments for cholestatic diseases, including PBC, nonalcoholic fatty liver disease, and portal hypertension [36].